The statistical analysis indicates that elevated TROP-2 expression correlates with poorer overall survival and adverse clinical and pathological features, including pT and pN status, clinical stage, and ENE, suggesting TROP-2 as a potential prognostic biomarker for PSCC patients. Here, TACSTD2 is linked to squamous cell carcinoma of penis.